NCT04975152View on ClinicalTrials.gov

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Merkel Cell CarcinomaCutaneous Squamous Cell Carcinoma

Interventions

DRUG

Cemiplimab-Rwlc

Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Sanofi-Synthelabo

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

collaborator

Sanofi-Synthelabo

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER